A citation-based method for searching scientific literature

F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel, Wallace Akerley, Alfons J M van den Eertwegh, Jose Lutzky, Paul Lorigan, Julia M Vaubel, Gerald P Linette, David Hogg, Christian H Ottensmeier, Celeste Lebbé, Christian Peschel, Ian Quirt, Joseph I Clark, Jedd D Wolchok, Jeffrey S Weber, Jason Tian, Michael J Yellin, Geoffrey M Nichol, Axel Hoos, Walter J Urba. N Engl J Med 2010
Times Cited: 9840



Caroline Robert, Jacob Schachter, Georgina V Long, Ana Arance, Jean Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U Blank, Omid Hamid, Christine Mateus, Ronnie Shapira-Frommer, Michele Kosh, Honghong Zhou, Nageatte Ibrahim, Scot Ebbinghaus, Antoni Ribas. N Engl J Med 2015
Times Cited: 3569




List of shared articles



Times cited


Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses?
Michael Kuske, Maximilian Haist, Thomas Jung, Stephan Grabbe, Matthias Bros. Cancers (Basel) 2022
0

Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study.
Li Zhou, Xiaowen Wu, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Lili Mao, Bin Lian, Bixia Tang, Xieqiao Yan,[...]. BMC Cancer 2022
0

Immune checkpoint inhibitors for the treatment of melanoma.
Francesco Sabbatino, Luigi Liguori, Stefano Pepe, Soldano Ferrone. Expert Opin Biol Ther 2022
0

Checkpoint Inhibitors and Induction of Celiac Disease-like Condition.
Aaron Lerner, Carina Benzvi. Biomedicines 2022
0

The evolutionary legacy of immune checkpoint inhibitors.
Itishree Kaushik, Sharavan Ramachandran, Carson Zabel, Shreyas Gaikwad, Sanjay K Srivastava. Semin Cancer Biol 2022
2

Anti-PD-1: When to Stop Treatment.
Y Jansen, A A M van der Veldt, G Awada, B Neyns. Curr Oncol Rep 2022
0

Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes.
Nick Lung-Ngai Ting, Harry Cheuk-Hay Lau, Jun Yu. Gut 2022
2

Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database.
Koki Kato, Tomohiro Mizuno, Takenao Koseki, Yoshimasa Ito, Kazuo Takahashi, Naotake Tsuboi, Shigeki Yamada. Front Pharmacol 2022
0

The Role of Surgery in the Treatment of Melanoma Pulmonary Metastases in the Modern Era.
Nathaniel Deboever, Hope A Feldman, Wayne L Hofstetter, Reza J Mehran, Ravi Rajaram, David C Rice, Jack A Roth, Boris Sepesi, Stephen G Swisher, Ara A Vaporciyan,[...]. J Surg Res 2022
0

Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer.
Nicola Gaynor, John Crown, Denis M Collins. Semin Cancer Biol 2022
35

Adjuvant treatment of high-risk melanoma - cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors.
Steffen Wahler, Alfred Müller, Sabine Fuchs, Johann-Matthias von der Schulenburg. Health Econ Rev 2022
0

Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.
Sara J Schonfeld, Margaret A Tucker, Eric A Engels, Graça M Dores, Joshua N Sampson, Meredith S Shiels, Stephen J Chanock, Lindsay M Morton. JAMA Netw Open 2022
0

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Jason J Luke, Piotr Rutkowski, Paola Queirolo, Michele Del Vecchio, Jacek Mackiewicz, Vanna Chiarion-Sileni, Luis de la Cruz Merino, Muhammad A Khattak, Dirk Schadendorf, Georgina V Long,[...]. Lancet 2022
2

Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities.
Tae Kon Kim, Esten N Vandsemb, Roy S Herbst, Lieping Chen. Nat Rev Drug Discov 2022
0

Early Tumor Size Reduction of at least 10% at the First Follow-Up Computed Tomography Can Predict Survival in the Setting of Advanced Melanoma and Immunotherapy.
Haidara Almansour, Saif Afat, Lina Maria Serna-Higuita, Teresa Amaral, Amadeus Schraag, Felix Peisen, Andreas Brendlin, Ferdinand Seith, Bernhard Klumpp, Thomas K Eigentler,[...]. Acad Radiol 2022
0

Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma.
C Robert, K D Lewis, R Gutzmer, D Stroyakovskiy, H Gogas, S Protsenko, R P Pereira, T Eigentler, P Rutkowski, L Demidov,[...]. Ann Oncol 2022
0